Immune Therapeutics, Inc. (IMUN)


Other OTC - Other OTC Delayed Price. Currency in USD
0.09+0.00 (+3.45%)
At close: 1:40 PM EDT
People also watch:
ORYNGWBUDIDGLDSIWRAP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.09
Prev Close0.09
Bid0.00 x
Ask0.00 x
Day's Range0.09 - 0.09
52wk Range0.07 - 0.28
1y Target EstN/A
Market Cap19.89M
P/E Ratio (ttm)-0.83
Beta-0.04
Volume41,000
Avg Vol (3m)269,439
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer

    ORLANDO, Fla., Aug. 23, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB-IMUN) ("IMUN"), headquartered in Orlando, Florida, is a clinical-stage biopharmaceutical company involved in the commercialization, manufacturing, distribution and marketing of its novel immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system. IMUN, in conjunction with the College of Medicine Malawi, has initiated a clinical study with LDN for the prevention of cervical cancer. This is an open-label, multicenter study designed to determine the safety and acceptability of a single-visit approach to cervical cancer prevention in patients.

  • Marketwired2 months ago

    Immune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT

    Immune Therapeutics, Inc. An Informational Shareholder Meeting will be held on Wednesday, August 17, 2016, at 10 a.m. EDT, at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.

  • PR Newswire4 months ago

    Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums

    ORLANDO, Fla., May 19, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (O TCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( " WHA " ) in Geneva, Switzerland to promote LodonalTM. The WHA is the decision-making body of the World Health Organization ("WHO"). The main functions of the WHA are to determine the policies of the organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget (www.who.int/mediacentre/events/2016/wha69/en/).